Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives

Beierwaltes, W H

doi:10.1002/mpo.2950150409

Title: Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives

Full Record
Other Related Research

Abstract

Between 7/3/80 and 5/7/86 we gave 32 of our neuroblastoma patients 62 diagnostic doses of metaiodobenzylguanidine (MIBG) and 12 patients 20 treatment doses. Our conclusion from our diagnostic dose studies is that MIBG should be used for staging the extent of neuroblastoma before therapy is started, because it may change the proposed staging and therapy. In MIBG therapy for neuroblastoma, our criteria for agreeing to treat a patient are based on calculations from a 4-day tracer dose study that assures that the patient will receive from his first therapy dose a tumor dose of at least 2000 rads/100 mCi, with a total body dose of not greater than 200 rads. Under these circumstances in children, the blood dose has been about 50 rads. The platelet count falls routinely with a 150-rad whole-body dose but never to dangerous levels. We have delivered tumor doses of 7000-34,600 rads on the first dose using 150-215 mCi. We have had objective regressions (as shown by before and after CAT scans) of 30-59% in volume of the principal tumor mass in 3 of the first 12 patients treated. All patients had Grade IV neuroblastoma with extensive previous surgery, radiation, and chemotherapy, with and without previousmore »« less

Authors:: Beierwaltes, W H

Publication Date:: Thu Jan 01 00:00:00 EST 1987

Research Org.:: Univ. of Michigan Medical Center, Ann Arbor

OSTI Identifier:: 5625513

Resource Type:: Journal Article

Journal Name:: Med. Pediatr. Oncol.; (United States)

Additional Journal Information:: Journal Volume: 15:4

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; NEOPLASMS; RADIOTHERAPY; RADIOPHARMACEUTICALS; THERAPEUTIC USES; CHILDREN; IODINE 131; PATIENTS; RADIATION DOSES; AGE GROUPS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; DRUGS; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; RADIOISOTOPES; RADIOLOGY; THERAPY; USES; 550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats


                    Beierwaltes, W H. Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives.  United States: N. p., 1987. 
        Web.  doi:10.1002/mpo.2950150409.

Copy to clipboard


                    Beierwaltes, W H. Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives.  United States.  https://doi.org/10.1002/mpo.2950150409

Copy to clipboard


                    Beierwaltes, W H. 1987.  
        "Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives".  United States.  https://doi.org/10.1002/mpo.2950150409.

Copy to clipboard


                    
@article{osti_5625513,

  title        = {Treatment of neuroblastoma with /sup 131/I-MIBG: dosimetric problems and perspectives},

  author       = {Beierwaltes, W H},

  abstractNote = {Between 7/3/80 and 5/7/86 we gave 32 of our neuroblastoma patients 62 diagnostic doses of metaiodobenzylguanidine (MIBG) and 12 patients 20 treatment doses. Our conclusion from our diagnostic dose studies is that MIBG should be used for staging the extent of neuroblastoma before therapy is started, because it may change the proposed staging and therapy. In MIBG therapy for neuroblastoma, our criteria for agreeing to treat a patient are based on calculations from a 4-day tracer dose study that assures that the patient will receive from his first therapy dose a tumor dose of at least 2000 rads/100 mCi, with a total body dose of not greater than 200 rads. Under these circumstances in children, the blood dose has been about 50 rads. The platelet count falls routinely with a 150-rad whole-body dose but never to dangerous levels. We have delivered tumor doses of 7000-34,600 rads on the first dose using 150-215 mCi. We have had objective regressions (as shown by before and after CAT scans) of 30-59% in volume of the principal tumor mass in 3 of the first 12 patients treated. All patients had Grade IV neuroblastoma with extensive previous surgery, radiation, and chemotherapy, with and without previous bone marrow transplants. MIBG therapy was most effective in patients with slower-growing tumors for whom initial treatment doses were 200 mCi or more.},

  doi          = {10.1002/mpo.2950150409},

  url          = {https://www.osti.gov/biblio/5625513},
  journal      = {Med. Pediatr. Oncol.; (United States)},
number       = ,

  volume       = 15:4,

  place        = {United States},

  year         = {Thu Jan 01 00:00:00 EST 1987},

  month        = {Thu Jan 01 00:00:00 EST 1987}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1002/mpo.2950150409

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial

Journal Article Klingebiel, T; Berthold, F; Treuner, J; ... - Medical and Pediatric Oncology; (United States)

From 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized neuroblastoma were treated with {sup 131}I-metaiodobenzylguanidine (mIBG) in several different treatment combinations. At initial diagnosis, 36 children had Evans stage IV and 11 stage III disease. In 16 of the 47 children, tumor recurred after complete remission prior to mIBG treatment, 26 of 47 progressed from residual or nonresponding tumor, and in 5 of 47 tumor progression during chemotherapy was observed. Altogether the children were treated with a total of 112 courses (range 1-6) with a mean dosage of 8.9 +/- 6.7 mCi/kg body weight/treatment course. Total dose wasmore »« less
https://doi.org/10.1002/mpo.2950190203
Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine

Journal Article Troncone, L; Riccardi, R; Montemaggi, P; ... - Med. Pediatr. Oncol.; (United States)

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity /sup 131/I-metaiodobenzylguanidine (/sup 131/I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an approach never previously reported. Single doses of /sup 131/I-MIBG varying from 70 to 184 mCi split into two parts were administered by slow i.v. infusion (4 to 8 hours) at 2- to 4-day intervals. The following results were obtained in the six evaluable patients: two patients showed transient stabilization of the disease; three had an objective response,more »« less
https://doi.org/10.1002/mpo.2950150417
The progressive and diffuse nature of neuroblastoma: Treatment with I-131 metaiodobenzylguanidine (I-131 MIBG). S-W

Conference Shen, ; Sisson, J; Hutchinson, R; ... - J. Nucl. Med.; (United States)

Neuroblastoma is a lethal and not uncommon cancer. In advanced disease, external beam radiation and chemotherapy bring no more than temporary remissions. Most neuroblastomas concentrate I-131 MIBG which then has therapeutic potential for these tumors. The authors treated the neuroblastomas of 7 patients, 20 mos-24 yrs of age, with I-131 MIBG. Factors were examined to explain the results. All but the oldest patient had extensive disease. Scintigraphy portrayed tumor infiltrations of the skeleton not otherwise detectable; in long bones, and, for 2 patients, in hands or feet. Hematopoiesis was precarious from the effects of both tumor and prior chemotherapy. Somemore »« less
Metaiodobenzylguanidine (MIBG) labeled with /sup 123/I//sup 131/I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986

Journal Article Feine, U; Mueller-Schauenburg, W; Treuner, J; ... - Med. Pediatr. Oncol.; (United States)

Our experience in scintigraphic diagnosis using /sup 123/I//sup 131/I-metaiodobenzylguanidine (MIBG) on 37 children with neuroblastomas stage III-IV is reported and discussed, together with the results obtained by other authors on MIBG diagnosis at the International Workshop of Pediatric Oncology held in Rome in September 1986. In our own investigation, 49 examinations were undertaken with /sup 123/I-MIBG and 66 with /sup 131/I-MIBG partly under therapy conditions with high-activity doses of /sup 131/I-MIBG. There were 29 neuroblastomas, 3 ganglioneuromas, and 3 ganglioneuroblastomas. The localization of all primary tumors was over 90%; for neuroblastomas with a high level of catecholamine excretion, over 95%.more »« less
https://doi.org/10.1002/mpo.2950150408
Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine

Journal Article Edeling, C; Frederiksen, P; Kamper, J; ... - Clin. Nucl. Med.; (United States)

Neuroblastoma is a lethal and not uncommon tumor in childhood. Early detection and display of the spread of the tumor is highly desirable for proper treatment. Nine children suspected of having neuroblastomas were examined by I-131 metaiodobenzylguanidine (I-131 MIBG) imaging. In two recent studies I-123 metaiodobenzylguanidine (I-123 MIBG) was used. A primary adrenal neuroblastoma was correctly identified in three cases. In two patients additional tumor sites were found. In one patient, who was in complete remission, no pathologic accumulation of I-131 MIBG was found. I-131 MIBG images were also normal in four patients with other types of neoplastic diseases. Amore »« less
https://doi.org/10.1097/00003072-198708000-00011

Similar Records